Qian Huang1, Xin-Wen Zhang2, Yu-Shui Ma3, Gai-Xia Lu3, Ru-Ting Xie4, Hui-Qiong Yang4, Zhong-Wei Lv3, Xiao-Ming Zhong5,6, Tao Liu7, Shi-Xiong Huang7, Da Fu8, Chun Xie1. 1. Department of Burn and Plastic Surgery, People's Hospital of New District Longhua Shenzhen, Shenzhen. 2. Department of Neurosurgery Surgery, Tongde Hospital of Zhejian Province, Hangzhou. 3. Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai. 4. Department of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai. 5. Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang. 6. Department of Radiology, Ganzhou City People's Hospital, Ganzhou. 7. Department of Neurology, People's Hospital of Hainan Province, Haikou. 8. Central Laboratory for Medical Research, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Abstract
BACKGROUND: An increasing understanding of the genes and molecular pathways of glioblastoma multiforme (GBM) can provide us a useful insight for the development of more effective targeted therapeutic. METHODS: To investigate the expression and clinical significance of miR-299 and its target genes in GBM, the expression levels of miR-299 and its target gene in human normal brain tissues and GBM were analyzed in silico using genes microarray and hierarchical clustering analysis followed by validation with quantitative RT-PCR. RESULTS: Our results show that miR-299 is up-regulated in GBM patients. Moreover, patients with low miR-299 expression had longer overall survival (OS) compared with those with high miR-299 expression. RNA polymerase II elongation factor, ELL2, was identified as a miR-299 direct target. High expression of ELL2 together with miR-299 down-regulation correlated with a shorter median OS. CONCLUSIONS: Our results provide the first evidence that ELL2 is a direct target of miR-299 and increased ELL2 expression and down-regulation of miR-299 are associated with GBM progression and poor prognosis in patients, suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
BACKGROUND: An increasing understanding of the genes and molecular pathways of glioblastoma multiforme (GBM) can provide us a useful insight for the development of more effective targeted therapeutic. METHODS: To investigate the expression and clinical significance of miR-299 and its target genes in GBM, the expression levels of miR-299 and its target gene in human normal brain tissues and GBM were analyzed in silico using genes microarray and hierarchical clustering analysis followed by validation with quantitative RT-PCR. RESULTS: Our results show that miR-299 is up-regulated in GBM patients. Moreover, patients with low miR-299 expression had longer overall survival (OS) compared with those with high miR-299 expression. RNA polymerase II elongation factor, ELL2, was identified as a miR-299 direct target. High expression of ELL2 together with miR-299 down-regulation correlated with a shorter median OS. CONCLUSIONS: Our results provide the first evidence that ELL2 is a direct target of miR-299 and increased ELL2 expression and down-regulation of miR-299 are associated with GBM progression and poor prognosis in patients, suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
Authors: Yi-Hsuan Wu; Rebecca E Graff; Michael N Passarelli; Joshua D Hoffman; Elad Ziv; Thomas J Hoffmann; John S Witte Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-17 Impact factor: 4.254
Authors: Joshua J Levy; Youdinghuan Chen; Nasim Azizgolshani; Curtis L Petersen; Alexander J Titus; Erika L Moen; Louis J Vaickus; Lucas A Salas; Brock C Christensen Journal: NPJ Syst Biol Appl Date: 2021-08-20